The comb antimicrobial market is projected to grow from USD 1.8 billion in 2026 to USD 2.7 billion by 2036, at a CAGR of 4.0%. Fixed-dose combos (systemic) will dominate with a 50.0% market share, while hospital-acquired infections will lead the application segment with a 35.0% share.